Multiplicity considerations for subgroup analysis subject to consistency constraint

Biometrical Journal

Volumn 55, Issue 3, 2013, Pages 444-462

  Alosh, Mohamed ^a   Huque, Mohammad F ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Consistency ensured multiplicity methods; Subgroup analysis; Targeted subgroup; Treatment by subgroup interaction

Indexed keywords

CHEMICAL REACTIONS;

CLINICAL TRIAL; CONSISTENCY CONSTRAINTS; CONSISTENCY ENSURED MULTIPLICITY METHOD; LABELINGS; REGULATORY GUIDANCE; SUBGROUP ANALYSE; TARGETED SUBGROUP; TREATMENT EFFECTS; TREATMENT-BY-SUBGROUP INTERACTION; TWO PATHS;

MEDICAL APPLICATIONS;

EID: 84876969027     PISSN: 03233847     EISSN: 15214036     Source Type: Journal    
DOI: 10.1002/bimj.201200065     Document Type: Article

References (21)

1. Alosh, M. and Huque, M. F. (2009). A flexible strategy for testing subgroups and overall population. Statistics in Medicine 8, 3-23.
2. Bender, R., Koch, A., Skipka, G., Kaiser, T. and Lange, S. (2010). No inconsistent trial assessments by NICE and IQWiG: different assessment goals may lead to different assessment results regarding subgroup analyses. Journal of Clinical Epidemiology 63, 1305-1307.
3. Bretz, F., Maurer, W., Brannath, W. and Posch, M. (2009). A graphical approach to sequentially rejective multiple testing procedures. Statistics in Medicine 28, 586-604.
4. Bretz, F., Posch, M., Glimm, E., Klinglmueller, F., Maurer W. and Rohmeyer, K. (2011). Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biometrical Journal 53, 894-913.
5. Burman, C. F., Sonesson, C. and Gilbaud, O. (2009). A recycling framework for the construction of Bonferroni-based multiple tests. Statistics in Medicine 28, 739-761.
6. Committee for Proprietary Medicinal Products. (2002). Points to consider on multiplicity issues in clinical trials London, UK: EMEA. Available at http://www.emea.europa.eu/pdfs/human/ewp/090899en.pdf
7. FDA Oncologic Drugs Advisory Committee, Released on December 16, 2008 transcript. Available at http://www.fda.gov/ohrms/dockets/ac/cder08.html
8. Grouin, J. M. Coste, M. and Lewis, J. (2005). Subgroup analyses in randomized clinical trials: statistical and regulatory issues. Journal of Biopharmaceutical Statistics 15, 869-82.
9. Hasford, J., Bramlage, P., Koch, G., Lehmacher, W., Einhäupl, K. and Rothwell, PM. (2010). Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed. Journal of Clinical Epidemiology 63, 1298-1304.
10. Huque, M. F. and Alosh, M. (2008). A flexible fixed-sequence testing method for hierarchically ordered correlated endpoints in clinical trials. Journal of Statistical Planning and Inference 138, 321-335.
11. Huque, M. F. and Alosh, M. (2012). A consistency adjusted strategy for accommodating an underpowered primary endpoint. Journal of Biopharmaceutical Statistics 22, 1-20.
12. Huque, M.F., Alosh, M. and Bhore, R. (2011). Addressing multiplicity issues of a composite endpoint and its components in clinical trials. Journal of Biopharmaceutical Statistics 21, 610-634.
13. ICH E9 Expert Working Group (1999). ICH harmonized tripartite guideline: statistical principles for clinical trials. Statistics in Medicine 18, 1905-1942.
14. Li, J. (2013). Testing each hypothesis marginally at alpha while still controlling FWER: how and when. Statistics in Medicine (in press).
15. Li, J. and Mehrotra, D. V. (2008). An efficient method for accommodating potentially under powered primary endpoints. Statistics in Medicine 27, 5377-5391.
16. Maitournam, A. and Simon, R. (2005). On the efficacy of targeted clinical trials. Statistics in Medicine 24, 329-339.
17. Millen, B. A. and Dmitrienko, A. (2011). Chain procedures: a class of flexible closed testing procedures with clinical trial applications. Statistics in Biopharmaceutical Research 3, 14-30.
18. Song, Y. and Chi, G.Y. (2007). A method for testing a prespecified subgroup in clinical trials. Statistics in Medicine 26, 3535-3549.
19. Wang, S., O'Neill, R. and Hung, J. (2007). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 7, 227-244.
20. Wiens, B. (2003). A fixed-sequence Bonferroni procedure for testing multiple endpoints. Pharmaceutical Statistics 2, 211-215.
21. Zhao, Y. D., Dmitrienko, A. and Tamura, R. (2010). Design and analysis considerations in clinical trials with a sensitive subpopulation. Statistics in Biopharmaceutical Research 2, 72-83.